Blog

Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24

Photo from Giuseppe Curigliano/X

Jun 5, 2024, 05:51

Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24

Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: .

“Congratulations to Giuseppe Curigliano for the outstanding presentation of the DESTINY-Breast06 trial at the ASCO Annual Meeting.

The improvement in progression-free survival in the group of patients treated with trastuzumab deruxtecan (T-DXd, Enhertu) compared to conventional chemotherapy is statistically significant and clinically meaningful.

Practice changing study!”

No alternative text description for this image

Source: Francisco J. Esteva/LinkedIn

ASCO ASCO24 cancer conventional chemotherapy DESTINY-Breast06 Trial Enhertu Francisco J. Esteva Giuseppe Curigliano Lenox Hill Hospital OncoDaily Oncology T-Dxd Trastuzumab deruxtecan

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

The Princess of Wales thanks The Royal Marsden for looking after her during her battle with cancer